How Clinicians Evaluate Tysabri-Associated PML Risk

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Occupational Exposure Concerns

If you or a loved one is taking Tysabri and experiencing new neurological symptoms, understanding how clinicians evaluate the concern for progressive multifocal leukoencephalopathy (PML) is critical. The medical community has developed structured diagnostic approaches based on symptom patterns and imaging findings. This page outlines the clinical signals that guide PML diagnosis and monitoring.

Tysabri and Progressive Multifocal Leukoencephalopathy: Medical Evidence

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and its clinical presentation includes progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis is confirmed through brain imaging and detection of JC virus DNA in cerebrospinal fluid. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing latent JC virus to reactivate and cause lytic infection of oligodendrocytes. This immunosuppressive effect is compounded by three identified risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning emphasizes that these factors should be considered in the context of expected benefit when initiating and continuing treatment. Adverse event reports from the FDA FAERS database list fatigue, multiple sclerosis relapse, headache, gait disturbance, and cognitive disorder among the most frequently reported events associated with Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While PML is a rare but devastating outcome, the drug's labeling requires that patients be monitored for any new sign or symptom suggestive of PML, and dosing should be withheld immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which mandates patient enrollment, medication guide review, and signed acknowledgment of risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Legal Considerations for Tysabri-Associated PML in California

For patients in California who have developed PML after Tysabri exposure, legal considerations include the statute of limitations for filing a product liability claim. In California, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For PML, the timeline between exposure and documented harm can vary. The drug's labeling notes that herpes infections have been reported from a few months to several years after starting Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), and PML risk increases with longer treatment duration, particularly beyond two years. This latency period may affect when a patient or their family becomes aware of the link between Tysabri and the disease. Adequacy of warnings is a central issue in potential litigation. The boxed warning clearly states that Tysabri increases PML risk and identifies specific risk factors. However, patients and attorneys may examine whether the warnings were sufficiently communicated to prescribers and patients, and whether the TOUCH program effectively ensured informed consent. The FDA's adverse event data show that cognitive disorder and memory impairment are among the frequently reported events (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI), which could be early signs of PML that might be overlooked. Attorney-related considerations for affected patients include gathering medical records documenting Tysabri use, PML diagnosis, and any prior immunosuppressant therapy. The statute of limitations clock may start at diagnosis or when PML is linked to Tysabri. Given the severity of PML—often leading to death or severe disability—prompt legal consultation is advisable to preserve claims. The risk-benefit analysis that physicians and patients must perform is complicated by the fact that Tysabri is effective for multiple sclerosis, but the potential for catastrophic harm requires careful monitoring and early intervention. In summary, Tysabri-associated PML is a well-documented adverse effect with a defined mechanistic basis and identifiable risk factors. The drug's labeling provides explicit warnings, but the latency of PML and the need for ongoing risk assessment create complex medical and legal landscapes for affected patients in California.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in California?

In California, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For PML, the clock may start at diagnosis or when the link to Tysabri is established. Given the latency of PML, prompt legal consultation is essential to preserve claims.

What are the risk factors for developing PML while on Tysabri?

The three identified risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the drug's boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What evidence should I gather if I am considering a Tysabri PML lawsuit?

You should gather medical records documenting Tysabri use, PML diagnosis, any prior immunosuppressant therapy, and records showing when you first learned of the potential link between Tysabri and PML. Also, keep records of any communications with healthcare providers regarding risks.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.